Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, was featured in a recent article published by Pharma Mirror Magazine. The article titled, “Neurology’s Growing Need for Disposable Technologies,” is written by Brain Scientific’s co-founder and executive chairman. The piece indicates that several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients. “When conditions like seizures, stroke and metabolic encephalopathy emerge, suddenly in a COVID-19 patient, it can negatively impact treatment outcomes and morbidity rates,” the article reads. “Facing evidence that these symptoms are common in COVID patients at all levels of treatment and among those without prior history of neurological conditions, healthcare workers must have access to efficient, disposable testing equipment to perform EEGs and brain scans in hospital and urgent care settings.”
To view the full article, visit https://ibn.fm/AdMu3
About Brain Scientific
Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork